Revvity (RVTY) 10-Q 5 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 29, 2015	Apr. 30, 2015
Document and Entity Information [Abstract]
Document Type	10-Q
Document Period End Date	29-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Amendment Flag	FALSE
Entity Registrant Name	PERKINELMER INC
Entity Central Index Key	31791
Current Fiscal Year End Date	-2
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		113,193,707
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes

Condensed_Consolidated_Income_

Condensed Consolidated Income Statements (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014
Sales Revenue, Goods, Net	$359,313	$365,485
Sales Revenue, Services, Net	167,588	165,125
Revenue	526,901	530,610
Cost of Goods Sold	184,609	189,284
Cost of Services	106,918	105,613
Cost of sales	291,527	294,897
Selling, general and administrative expenses	145,873	152,437
Research and development expenses	32,120	29,379
Restructuring and lease charges, net	0	2,135
Operating income from continuing operations	57,381	51,762
Interest and other expense, net	9,421	11,289
Income from continuing operations before income taxes	47,960	40,473
Provision for income taxes	7,649	5,522
Net income from continuing operations	40,311	34,951
Loss from discontinued operations before income taxes	-37	-1,030
Gain (Loss) on disposition of discontinued operations before income taxes	-13	-72
(Benefit from) provision for income taxes on discontinued operations and dispositions	-73	-375
Net income (loss) from discontinued operations and dispositions	23	-727
Net income	$40,334	$34,224
Basic earnings (loss) per share:
Net income from continuing operations (per share)	$0.36	$0.31
Net income (loss) from discontinued operations and dispositions (per share)	$0	($0.01)
Net Income (per share)	$0.36	$0.30
Diluted earnings (loss) per share:
Net income from continuing operations (per share)	$0.36	$0.31
Net income (loss) from discontinued operations and dispositions (per share)	$0	($0.01)
Net income (per share)	$0.36	$0.30
Weighted average shares of common stock outstanding:
Basic (in shares)	112,641	112,553
Diluted (in shares)	113,439	113,777
Cash dividends per common share	$0.07	$0.07

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014
Net income	$40,334	$34,224
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	-23,697	634
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax	-29	-32
Other Comprehensive Income (Loss), Net of Tax	-23,726	602
Comprehensive Income, Net of Tax, Attributable to Parent	$16,608	$34,826

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 29, 2015	Dec. 28, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$168,924	$174,821
Accounts receivable, net	415,378	470,563
Inventories, net	291,120	285,457
Other current assets	147,113	137,710
Total current assets	1,022,535	1,068,551
Property, plant and equipment, net:
At cost	485,101	492,814
Accumulated depreciation	-316,602	-316,620
Property, plant and equipment, net	168,499	176,194
Marketable securities and investments	1,598	1,568
Intangible assets, net	470,012	490,265
Goodwill	2,253,208	2,284,077
Other assets, net	112,419	113,420
Total assets	4,028,271	4,134,075
Current liabilities:
Short-term debt	1,083	1,075
Accounts payable	157,471	173,953
Restructuring Reserve, Current	13,312	17,124
Accrued expenses	376,585	403,021
Current liabilities of discontinued operations	2,130	2,137
Total current liabilities	550,581	597,310
Long-term debt	1,014,666	1,051,892
Long-term liabilities	403,139	442,771
Total liabilities	1,968,386	2,091,973
Commitments and contingencies (see Note 18)
Stockholders' equity:
Preferred stock-$1 par value per share, authorized 1,000,000 shares; none issued or outstanding	0	0
Common stock-$1 par value per share, authorized 300,000,000 shares; issued and outstanding	113,190	112,481
Capital in excess of par value	102,673	94,276
Retained earnings	1,842,948	1,810,545
Accumulated other comprehensive loss	1,074	24,800
Total stockholders' equity	2,059,885	2,042,102
Total liabilities and stockholders' equity	$4,028,271	$4,134,075

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 29, 2015	Dec. 28, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value	$1	$1
Preferred stock, authorized	1,000,000	1,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$1	$1
Common stock, authorized	300,000,000	300,000,000
Common stock, issued	113,190,000	112,481,000
Common stock, outstanding	113,190,000	112,481,000

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014
Operating activities:
Net income	$40,334	$34,224
Add: net income from discontinued operations and dispositions, net of income taxes	-23	727
Net income from continuing operations	40,311	34,951
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations:
Restructuring and lease charges, net	0	2,135
Depreciation and amortization	28,334	29,328
Stock-based compensation	3,987	4,516
Amortization of deferred debt issuance costs	312	304
Amortization of acquired inventory revaluation	4,850	0
Changes in operating assets and liabilities which provided (used) cash, excluding effects from companies purchased and divested:
Accounts receivable, net	37,582	26,732
Inventories, net	-22,498	-17,719
Accounts payable	-12,335	959
Accrued expenses and other	-42,895	-13,093
Net cash provided by operating activities of continuing operations	37,648	68,113
Net cash (used in) provided by operating activities of discontinued operations	15	-402
Net cash provided by operating activities	37,663	67,711
Investing activities:
Capital expenditures	-4,479	-6,020
Changes in restricted cash balances	-59	0
Payments for acquisitions and investments, net of cash and cash equivalents acquired	-4,619	0
Net cash used in investing activities	-9,039	-6,020
Financing activities:
Payments on debt	-98,000	-95,000
Proceeds from borrowings	61,000	90,000
Payments of debt issuance costs	0	-1,724
Payments for (Proceeds from) Hedge, Financing Activities	15,563	0
Payments on other credit facilities	-263	-252
Proceeds from stock options exercised	8,840	7,231
Purchases of common stock	-3,954	-3,916
Dividends paid	-7,876	-7,887
Net cash (used in) provided by financing activities	-24,690	-11,548
Effect of exchange rate changes on cash and cash equivalents	-9,831	728
Net (decrease) increase in cash and cash equivalents	-5,897	50,871
Cash and cash equivalents at beginning of period	174,821	173,242
Cash and cash equivalents at end of period	$168,924	$224,113

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Mar. 29, 2015
Accounting Policies [Abstract]
Basis of Accounting [Text Block]	Basis of Presentation
	The condensed consolidated financial statements included herein have been prepared by PerkinElmer, Inc. (the “Company”), without audit, in accordance with accounting principles generally accepted in the United States of America (the “U.S.” or the "United States") and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information in the footnote disclosures of the financial statements has been condensed or omitted where it substantially duplicates information provided in the Company’s latest audited consolidated financial statements, in accordance with the rules and regulations of the SEC. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes included in its Annual Report on Form 10-K for the fiscal year ended December 28, 2014, filed with the SEC (the “2014 Form 10-K”). The balance sheet amounts at December 28, 2014 in this report were derived from the Company’s audited 2014 consolidated financial statements included in the 2014 Form 10-K. The condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods indicated. The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts and classifications of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three months ended March 29, 2015 and March 30, 2014, respectively, are not necessarily indicative of the results for the entire fiscal year or any future period. The Company has evaluated subsequent events from March 29, 2015 through the date of the issuance of these condensed consolidated financial statements and has determined that no material subsequent events have occurred that would affect the information presented in these condensed consolidated financial statements or would require additional disclosure.
	The Company’s fiscal year ends on the Sunday nearest December 31. The Company reports fiscal years under a 52/53 week format. Under this method, certain years will contain 53 weeks. The fiscal year ending January 3, 2016 will include 53 weeks and the extra week will be included in the third quarter. The fiscal year ended December 28, 2014 included 52 weeks.
	Recently Adopted and Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s condensed consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations.
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers. Under this new guidance, an entity should use a five-step process to recognize revenue, which depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires new disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The initial provisions of this guidance are effective for interim and annual periods beginning after December 15, 2016. In April 2015, the Financial Accounting Standards Board tentatively decided to defer the effective date of the standard for one year to annual periods beginning after December 15, 2017, with early adoption permitted for annual periods beginning after December 15, 2016. The Company is evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company’s consolidated financial position, results of operations and cash flows.
	In April 2015, the Financial Accounting Standards Board issued Accounting Standards Update No. 2015-04, Practical Expedient for the Measurement Date of an Employer’s Defined Benefit Obligation and Plan Assets. Under this new guidance, an entity with a fiscal year-end that does not coincide with a calendar month-end (for example an entity that has a 52/53 week fiscal year) has the ability, as a practical expedient, to measure its defined benefit retirement obligations and related plan assets as of the month-end that is closest to its fiscal year end. An entity that uses this election must disclose it and consistently apply the practical expedient from year to year and to all of its defined benefit plans. The provisions of this guidance are effective for interim and annual periods beginning after December 15, 2015. Prospective application is required, and early adoption is permitted. The Company is evaluating the requirements of this guidance and expects to early adopt this guidance for its current fiscal year ending January 3, 2016 and for any interim period during the current fiscal year. The adoption is not expected to have a material impact on the Company's consolidated financial position, results of operations and cash flows.

Business_Combinations

Business Combinations	3 Months Ended
	Mar. 29, 2015
Business Combinations [Abstract]
Business Combinations	Business Combinations
	Acquisitions in fiscal year 2015
	During the first three months of fiscal year 2015, the Company completed the acquisition of two businesses for total consideration of $4.7 million, in cash. The excess of the purchase prices over the fair values of each of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and have been allocated to goodwill, of which $0.03 million is tax deductible. The Company reported the operations for these acquisitions within the results of the Company's Human Health and Environmental Health segments from the acquisition dates. As of March 29, 2015, the purchase accounting allocations related to these acquisitions were preliminary. In addition, subsequent to March 29, 2015, the Company completed the acquisition of a business for total consideration of $14.0 million, in cash, as of the closing date. The operations for this acquisition will be reported within the results of the Company's Environmental Health segment.
	Acquisitions in fiscal year 2014
	Acquisition of Perten Instruments Group AB. In December 2014, the Company acquired all of the outstanding stock of Perten Instruments Group AB ("Perten"). Perten is a provider of analytical instruments and services for quality control of food, grain, flour and feed. The Company expects this acquisition to enhance its industrial, environmental and safety business by expanding the Company's product offerings to the academic and industrial end markets. The Company paid the shareholders of Perten $269.9 million in cash for the stock of Perten. The excess of the purchase price over the fair value of the acquired net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and has been allocated to goodwill, none of which is tax deductible. The Company has reported the operations for this acquisition within the results of the Company’s Environmental Health segment from the acquisition date. Identifiable definite-lived intangible assets, such as core technology, customer relationships and trade names, acquired as part of this acquisition had weighted average amortization periods of approximately 5 to 10 years.
	Other acquisitions in fiscal year 2014. In addition to the Perten acquisition, the Company completed the acquisition of two businesses in fiscal year 2014 for total consideration of $18.0 million in cash and $4.3 million of assumed debt. The excess of the purchase price over the fair value of each of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and has been allocated to goodwill, none of which is tax deductible. The Company reported the operations for these acquisitions within the results of the Human Health and Environmental Health segments from the acquisition dates. As of March 29, 2015, the purchase accounting allocations related to acquisitions completed during fiscal year 2014 were preliminary.
	The total purchase price for the acquisitions in fiscal year 2014 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows:
		Perten			2014 Other
		(Preliminary)
		(In thousands)
	Fair value of business combination:
	Cash payments	$	269,937		$	17,898
	Working capital and other adjustments	—			151
	Less: cash acquired	(16,732		)	(124		)
	Total	$	253,205		$	17,925
	Identifiable assets acquired and liabilities assumed:
	Current assets	$	32,805		$	1,965
	Property, plant and equipment	1,485			125
	Other assets	—			364
	Identifiable intangible assets:
	Core technology	16,000			1,705
	Trade names	7,000			—
	Customer relationships	87,000			6,800
	IPR&D	—			1,266
	Goodwill	164,164			15,981
	Deferred taxes	(31,454		)	(3,072		)
	Deferred revenue	—			(589		)
	Liabilities assumed	(16,195		)	(2,333		)
	Debt assumed	(7,600		)	(4,287		)
	Total	$	253,205		$	17,925
	The preliminary allocations of the purchase prices for acquisitions completed in fiscal years 2015 and 2014 were based upon initial valuations. The Company's estimates and assumptions underlying the initial valuations are subject to the collection of information necessary to complete its valuations within the measurement periods, which are up to one year from the respective acquisition dates. The primary areas of the preliminary purchase price allocations that are not yet finalized relate to the fair value of certain tangible and intangible assets acquired and liabilities assumed, assets and liabilities related to income taxes and related valuation allowances, and residual goodwill. The Company expects to continue to obtain information to assist in determining the fair values of the net assets acquired at the acquisition dates during the measurement periods. During the measurement periods, the Company will adjust assets or liabilities if new information is obtained about facts and circumstances that existed as of the acquisition dates that, if known, would have resulted in the recognition of those assets and liabilities as of those dates. Adjustments to the preliminary allocation of the purchase prices during the measurement period require the revision of comparative prior period financial information when reissued in subsequent financial statements. The effect of adjustments to the allocation of the purchase prices made during the measurement periods would be as if the adjustments had been completed on the acquisition dates. The effects of any such adjustments, if material, may cause changes in depreciation, amortization, or other income or expense recognized in prior periods. All changes that do not qualify as adjustments made during the measurement periods are included in current period earnings.
	Allocations of the purchase price for acquisitions are based on estimates of the fair value of the net assets acquired and are subject to adjustment upon finalization of the purchase price allocations. The accounting for business combinations requires estimates and judgments as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair values for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash. Increases or decreases in the fair value of contingent consideration liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds or product development milestones during the earnout period.
	The Company may have to pay contingent consideration, related to acquisitions with open contingency periods, of up to $31.4 million as of March 29, 2015. As of March 29, 2015, the Company has recorded contingent consideration obligations relating to the acquisition of Tetra Teknolojik Sistemler Limited Sirketi with an estimated fair value of $0.1 million. The earnout period for acquisitions with open contingency periods does not exceed three years from the respective acquisition date. If the actual results differ from the estimates and judgments used in these fair values, the amounts recorded in the condensed consolidated financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of definite-lived intangible assets or the recognition of additional consideration which would be expensed.
	Total transaction costs related to acquisition activities for the three months ended March 29, 2015 and March 30, 2014 were $0.2 million and $0.1 million, respectively, which were expensed as incurred and recorded in selling, general and administrative expenses in the Company's condensed consolidated statements of operations.

Discontinued_Operations

Discontinued Operations	3 Months Ended
	Mar. 29, 2015
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations
	As part of the Company’s continuing efforts to focus on higher growth opportunities, the Company has discontinued certain businesses. The Company has accounted for these businesses as discontinued operations and, accordingly, has presented the results of operations and related cash flows as discontinued operations for all periods presented. Any remaining assets and liabilities of these businesses have been presented separately, and are reflected within assets and liabilities from discontinued operations in the accompanying condensed consolidated balance sheets as of March 29, 2015 and December 28, 2014.
	In May 2014, the Company’s management approved the shutdown of its microarray-based diagnostic testing laboratory in the United States, which had been reported within the Human Health segment. The Company determined that, with the lack of adequate reimbursement from health care payers, the microarray-based diagnostic testing laboratory in the United States would need significant investment in its operations to reduce costs in order to effectively compete in the market. The shutdown of the microarray-based diagnostic testing laboratory in the United States resulted in a $0.1 million net pre-tax loss primarily related to the disposal of fixed assets, which was partially offset by the sale of a building in fiscal year 2014.
	During the first three months of each of fiscal years 2015 and 2014, the Company settled various commitments related to the divestiture of other discontinued operations. The Company recognized net pre-tax losses of $0.01 million and $0.1 million for the three months ended March 29, 2015 and March 30, 2014, respectively. These losses were recognized as a loss on disposition of discontinued operations.
	Summary pre-tax operating results of discontinued operations, which include the periods prior to disposition, were as follows:
		Three Months Ended
		March 29,			March 30,
		2015			2014
		(In thousands)
	Sales	$	20		$	1,294
	Costs and expenses	57			2,324
	Loss from discontinued operations before income taxes	$	(37	)	$	(1,030	)
	The Company recorded tax benefits of $0.1 million and $0.4 million on discontinued operations and dispositions for the three months ended March 29, 2015 and March 30, 2014, respectively.

Restructuring_and_Lease_Charge

Restructuring and Lease Charges, Net	3 Months Ended
	Mar. 29, 2015
Restructuring and Related Activities [Abstract]
Restructuring and Lease Charges, Net	Restructuring and Contract Termination Charges, Net
	The Company's management has approved a series of restructuring actions related to the impact of acquisitions and divestitures, the alignment of the Company's operations with its growth strategy, the integration of its business units and productivity initiatives. The current portion of restructuring and contract termination charges is recorded in accrued restructuring and contract termination charges and the long-term portion of restructuring and contract termination charges is recorded in long-term liabilities. The activities associated with these plans have been reported as restructuring and contract termination charges, net, and are included as a component of operating expenses from continuing operations.
	The Company implemented a restructuring plan in the third quarter of fiscal year 2014 consisting of workforce reductions principally intended to realign resources to emphasize growth initiatives (the "Q3 2014 Plan"). The Company implemented restructuring plans in the second and first quarters of fiscal year 2014 consisting of workforce reductions principally intended to focus resources on higher growth end markets (the "Q2 2014 Plan" and "Q1 2014 Plan", respectively). Details of the plans initiated in previous years (“Previous Plans”) are discussed more fully in Note 4 to the audited consolidated financial statements in the 2014 Form 10-K. The Company also has terminated various contractual commitments in connection with certain disposal activities and has recorded charges, to the extent applicable, for the costs of terminating these contracts before the end of their terms and the costs that will continue to be incurred for the remaining terms without economic benefit to the Company.
	The following table summarizes the number of employees reduced, the initial restructuring or contract termination charges by operating segment, and the dates by which payments were substantially completed, or the expected dates by which payments will be substantially completed, for restructuring actions during fiscal year 2014:
				Initial Restructuring or Contract Termination Charges							Total		Date or Expected Date Payments Substantially Completed by
		Headcount Reduction		Human Health				Environmental Health
		(In thousands, except headcount data)
	Q3 2014 Plan	152		$	7,126			$	5,925		$	13,051	Q3 FY2015
	Q2 2014 Plan	22		545				190			735		Q2 FY2015
	Q1 2014 Plan	17		370				197			567		Q4 FY2014
	2014 Contract Termination Charges	—		—				1,545			1,545		Q4 FY2015
	The Company expects to make payments under the Previous Plans for remaining residual lease obligations, with terms varying in length, through fiscal year 2022.
	At March 29, 2015, the Company had $19.2 million recorded for accrued restructuring and contract termination charges, of which $13.3 million was recorded in short-term accrued restructuring and contract termination charges and $5.9 million was recorded in long-term liabilities. At December 28, 2014, the Company had $23.8 million recorded for accrued restructuring and contract termination charges, of which $17.1 million was recorded in short-accrued restructuring and $6.7 million was recorded in long-term liabilities. The following table summarizes the Company's restructuring and contract termination accrual balances and related activity by restructuring plan, as well as contract termination, during the three months ended March 29, 2015:
		Balance at December 28, 2014			2015 Amounts Paid				Balance at March 29, 2015
		(In thousands)
	Q3 2014 Plan	$	10,059		$	(3,139	)		$	6,920
	Q2 2014 Plan	251			(8		)		243
	Q1 2014 Plan	92			—				92
	Previous Plans	13,124			(1,427		)		11,697
	Restructuring	23,526			(4,574		)		18,952
	Contract Termination	304			(89		)		215
	Total Restructuring and Contract Termination	$	23,830		$	(4,663	)		$	19,167

Interest_and_Other_Expense_Inc

Interest and Other Expense (Income), Net	3 Months Ended
	Mar. 29, 2015
Other Income and Expenses [Abstract]
Interest and Other Expense (Income), Net	Interest and Other Expense, Net
	Interest and other expense, net, consisted of the following:
		Three Months Ended
		March 29,			March 30,
		2015			2014
		(In thousands)
	Interest income	$	(209	)	$	(94	)
	Interest expense	9,388			9,219
	Other expense, net	242			2,164
	Total interest and other expense, net	$	9,421		$	11,289

Inventories_Net

Inventories, Net	3 Months Ended
	Mar. 29, 2015
Inventory Disclosure [Abstract]
Inventories, Net	Inventories
	Inventories as of March 29, 2015 and December 28, 2014 consisted of the following:
		March 29,		December 28,
		2015		2014
		(In thousands)
	Raw materials	$	98,042	$	96,169
	Work in progress	20,106		18,783
	Finished goods	172,972		170,505
	Total inventories	$	291,120	$	285,457

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 29, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	The Company regularly reviews its tax positions in each significant taxing jurisdiction in the process of evaluating its unrecognized tax benefits. The Company makes adjustments to its unrecognized tax benefits when: (i) facts and circumstances regarding a tax position change, causing a change in management’s judgment regarding that tax position; (ii) a tax position is effectively settled with a tax authority at a differing amount; and/or (iii) the statute of limitations expires regarding a tax position.
	At March 29, 2015, the Company had gross tax effected unrecognized tax benefits of $30.7 million, of which $26.9 million, if recognized, would affect the continuing operations effective tax rate. The remaining amount, if recognized, would affect discontinued operations.
	The Company believes that it is reasonably possible that approximately $5.2 million of its uncertain tax positions at March 29, 2015, including accrued interest and penalties, and net of tax benefits, may be resolved over the next twelve months as a result of lapses in applicable statutes of limitations and potential settlements. Various tax years after 2007 remain open to examination by certain jurisdictions in which the Company has significant business operations, such as China, Finland, Germany, Italy, Netherlands, Singapore, the United Kingdom and the United States. The tax years under examination vary by jurisdiction.
	During the first three months of fiscal years 2015 and 2014, the Company recorded net discrete income tax benefits of $1.8 million and $2.0 million, respectively, primarily for reversals of uncertain tax position reserves and resolution of other tax matters.

Debt

Debt	3 Months Ended
	Mar. 29, 2015
Debt Disclosure [Abstract]
Debt	Debt
	Senior Unsecured Revolving Credit Facility. On January 8, 2014, the Company refinanced its debt held under a previous senior unsecured revolving credit facility and entered into a new senior unsecured revolving credit facility. The Company's senior unsecured revolving credit facility provides for $700.0 million of revolving loans and has an initial maturity of January 8, 2019. As of March 29, 2015, undrawn letters of credit in the aggregate amount of $12.2 million were treated as issued and outstanding under the senior unsecured revolving credit facility. As of March 29, 2015, the Company had $208.8 million available for additional borrowing under the facility. The Company uses the senior unsecured revolving credit facility for general corporate purposes, which may include working capital, refinancing existing indebtedness, capital expenditures, share repurchases, acquisitions and strategic alliances. The interest rates under the senior unsecured revolving credit facility are based on the Eurocurrency rate or the base rate at the time of borrowing, plus a margin. The base rate is the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by JP Morgan Chase Bank, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) one-month Libor plus 1.00%. At March 29, 2015, borrowings under the senior unsecured revolving credit facility were accruing interest primarily based on the Eurocurrency rate. The Eurocurrency margin as of March 29, 2015 was 108 basis points. The weighted average Eurocurrency interest rate as of March 29, 2015 was 0.18%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 1.26%. At March 29, 2015 and December 28, 2014, the Company had $479.0 million and $516.0 million, respectively, of borrowings in U.S. dollars outstanding under the senior unsecured revolving credit facility. The credit agreement for the facility contains affirmative, negative and financial covenants and events of default similar to those contained in the credit agreement for the Company's previous facility. The financial covenants in the Company's senior unsecured revolving credit facility include a debt-to-capital ratio, and two contingent covenants, a maximum consolidated leverage ratio and a minimum consolidated interest coverage ratio, applicable if the Company's credit rating is downgraded below investment grade.
	5% Senior Unsecured Notes due in 2021. On October 25, 2011, the Company issued $500.0 million aggregate principal amount of senior unsecured notes due in 2021 (the “2021 Notes”) in a registered public offering and received $496.9 million of net proceeds from the issuance. The 2021 Notes were issued at 99.372% of the principal amount, which resulted in a discount of $3.1 million. As of both March 29, 2015 and December 28, 2014, the 2021 Notes had an aggregate carrying value of $497.7 million, net of $2.3 million of unamortized original issue discount. The 2021 Notes mature in November 2021 and bear interest at an annual rate of 5%. Interest on the 2021 Notes is payable semi-annually on May 15th and November 15th each year. Prior to August 15, 2021 (three months prior to their maturity date), the Company may redeem the 2021 Notes in whole or in part, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the 2021 Notes to be redeemed, plus accrued and unpaid interest, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the 2021 Notes being redeemed, discounted on a semi-annual basis, at the Treasury Rate plus 45 basis points, plus accrued and unpaid interest. At any time on or after August 15, 2021 (three months prior to their maturity date), the Company may redeem the 2021 Notes, at its option, at a redemption price equal to 100% of the principal amount of the 2021 Notes to be redeemed plus accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the 2021 Notes) and a contemporaneous downgrade of the 2021 Notes below investment grade, each holder of 2021 Notes will have the right to require the Company to repurchase such holder's 2021 Notes for 101% of their principal amount, plus accrued and unpaid interest.
	Financing Lease Obligations. In fiscal year 2012, the Company entered into agreements with the lessors of certain buildings that the Company is currently occupying and leasing to expand those buildings. The Company provided a portion of the funds needed for the construction of the additions to the buildings, and as a result the Company was considered the owner of the buildings during the construction period. At the end of the construction period, the Company was not reimbursed by the lessors for all of the construction costs. The Company is therefore deemed to have continuing involvement and the leases qualify as financing leases under sale-leaseback accounting guidance, representing debt obligations for the Company and non-cash investing and financing activities. As a result, the Company capitalized $29.3 million in property and equipment, net, representing the fair value of the buildings with a corresponding increase to debt. The Company has also capitalized $11.5 million in additional construction costs necessary to complete the renovations to the buildings, which were funded by the lessors, with a corresponding increase to debt. At March 29, 2015, the Company had $39.0 million recorded for these financing lease obligations, of which $1.1 million was recorded as short-term debt and $37.9 million was recorded as long-term debt. At December 28, 2014, the Company had $39.3 million recorded for these financing lease obligations, of which $1.1 million was recorded as short-term debt and $38.2 million was recorded as long-term debt. The buildings are being depreciated on a straight-line basis over the terms of the leases to their estimated residual values, which will equal the remaining financing obligation at the end of the lease term. At the end of the lease term, the remaining balances in property, plant and equipment, net and debt will be reversed against each other.

Earnings_Per_Share

Earnings Per Share	3 Months Ended
	Mar. 29, 2015
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share
	Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations:
		Three Months Ended
		March 29,	March 30,
		2015	2014
		(In thousands)
	Number of common shares—basic	112,641	112,553
	Effect of dilutive securities:
	Stock options	677	1,052
	Restricted stock awards	121	172
	Number of common shares—diluted	113,439	113,777
	Number of potentially dilutive securities excluded from calculation due to antidilutive impact	932	459
	Antidilutive securities include outstanding stock options with exercise prices and average unrecognized compensation cost in excess of the average fair market value of common stock for the related period. Antidilutive options were excluded from the calculation of diluted net income per share and could become dilutive in the future.

Industry_Segment_Information

Industry Segment Information	3 Months Ended
	Mar. 29, 2015
Segment Reporting [Abstract]
Industry Segment Information	Industry Segment Information
	The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income. Intersegment revenue and transfers are not significant. The Company’s management reviews the results of the Company’s operations by the Human Health and Environmental Health operating segments. The accounting policies of the operating segments are the same as those described in Note 1 to the audited consolidated financial statements in the 2014 Form 10-K.
	The Company realigned its organization at the beginning of fiscal year 2015 to enable the Company to both deliver complete solutions targeted towards certain end markets and develop value-added applications and solutions to foster further expansion of those markets. OneSource, the multivendor service offering business that serves the life sciences end market, was moved from the Environmental Health segment into the Human Health segment. The results reported for the three months ended March 29, 2015 reflect this new alignment of the Company's operating segments. Financial information in this report relating to the three months ended March 30, 2014 and the fiscal year ended 2014 have been retrospectively adjusted to reflect the changes to the operating segments. The principal products and services of the Company's two operating segments are:
	•	Human Health.    Develops diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. The Human Health segment serves both the diagnostics and research markets.
	•	Environmental Health.    Provides products, services and solutions to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets.
	The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments.
	Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below:
		Three Months Ended
		March 29,			March 30,
		2015			2014
		(In thousands)
	Human Health
	Product revenue	$	231,147		$	239,030
	Service revenue	94,906			91,003
	Total revenue	326,053			330,033
	Operating income from continuing operations	55,882			43,982
	Environmental Health
	Product revenue	128,166			126,455
	Service revenue	72,682			74,122
	Total revenue	200,848			200,577
	Operating income from continuing operations	11,346			21,607
	Corporate
	Operating loss from continuing operations(1)	(9,847		)	(13,827		)
	Continuing Operations
	Product revenue	359,313			365,485
	Service revenue	167,588			165,125
	Total revenue	526,901			530,610
	Operating income from continuing operations	57,381			51,762
	Interest and other expense, net (see Note 5)	9,421			11,289
	Income from continuing operations before income taxes	$	47,960		$	40,473
	____________________________
	(1)	In 2002, Enzo Biochem, Inc. and Enzo Life Sciences, Inc. (collectively, “Enzo”) filed a complaint that alleged that the Company separately and together with other defendants breached distributorship and settlement agreements with Enzo, infringed Enzo's patents, engaged in unfair competition and fraud, and committed torts against Enzo by, among other things, engaging in commercial development and exploitation of Enzo's patented products and technology. The Company entered into a settlement agreement with Enzo dated June 20, 2014 and during fiscal year 2014 paid $7.0 million into a designated escrow account to resolve this matter, of which $3.7 million had been accrued in previous years and $3.3 million was recorded in the second quarter of fiscal year 2014. In addition, $3.2 million of expenses were incurred and recorded in preparation for the trial during the three months ended March 30, 2014.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 29, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders’ Equity
	Comprehensive Income:
	The components of accumulated other comprehensive income consisted of the following:
		March 29,			December 28,
		2015			2014
		(In thousands)
	Foreign currency translation adjustments	$	(365	)	$	23,332
	Unrecognized prior service costs, net of income taxes	1,575			1,575
	Unrealized net losses on securities, net of income taxes	(136		)	(107		)
	Accumulated other comprehensive income	$	1,074		$	24,800
	Stock Repurchase Program:
	On October 23, 2014, the Board of Directors (the "Board") authorized the Company to repurchase up to 8.0 million shares of common stock under a stock repurchase program (the "Repurchase Program"). The Repurchase Program will expire on October 23, 2016 unless terminated earlier by the Board, and may be suspended or discontinued at any time. During the three months ended March 29, 2015, the Company did not repurchase shares of common stock in the open market, under the Repurchase Program. As of March 29, 2015, 7.4 million shares of the Company’s common stock remained available for repurchase from the 8.0 million shares authorized by the Board under the Repurchase Program.
	The Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans and to satisfy obligations related to the exercise of stock options made pursuant to the Company's equity incentive plans. During the three months ended March 29, 2015, the Company repurchased 85,739 shares of common stock for this purpose at an aggregate cost of $4.0 million. The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value.
	Dividends:
	The Board declared a regular quarterly cash dividend of $0.07 per share for the first quarter of fiscal year 2015 and in each quarter of fiscal year 2014. At March 29, 2015, the Company has accrued $7.9 million for dividends declared on January 23, 2015 for the first quarter of fiscal year 2015, payable in May 2015. On April 27, 2015, the Company announced that the Board had declared a quarterly dividend of $0.07 per share for the second quarter of fiscal year 2015 that will be payable in August 2015. In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Stock_Plans

Stock Plans	3 Months Ended
	Mar. 29, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Plans	Stock Plans
	In addition to the Company's Employee Stock Purchase Plan, the Company utilizes one stock-based compensation plan, the 2009 Incentive Plan (the “2009 Plan”). Under the 2009 Plan, 10.0 million shares of the Company's common stock are authorized for stock option grants, restricted stock awards, performance units and stock grants as part of the Company’s compensation programs. In addition to shares of the Company’s common stock originally authorized for issuance under the 2009 Plan, the 2009 Plan includes shares of the Company’s common stock previously granted under the Amended and Restated 2001 Incentive Plan and the 2005 Incentive Plan that were canceled or forfeited without the shares being issued.
	The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance units and stock grants, net of estimated forfeitures, included in the Company’s condensed consolidated statements of operations for the three months ended March 29, 2015 and March 30, 2014:
		Three Months Ended
		March 29,			March 30,
		2015			2014
		(In thousands)
	Cost of product and service revenue	$	249		$	333
	Research and development expenses	159			141
	Selling, general and administrative expenses	3,579			4,042
	Total stock-based compensation expense	$	3,987		$	4,516
	The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $1.3 million and $1.6 million for the three months ended March 29, 2015 and March 30, 2014, respectively. Stock-based compensation costs capitalized as part of inventory were $0.4 million and $0.3 million as of March 29, 2015 and March 30, 2014, respectively.
	Stock Options: The fair value of each option grant is estimated using the Black-Scholes option pricing model. The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows:
		Three Months Ended
		March 29,		March 30,
		2015		2014
	Risk-free interest rate	1.3	%	1.5	%
	Expected dividend yield	0.6	%	0.7	%
	Expected lives	5 years		5 years
	Expected stock volatility	26.5	%	30.9	%
	The following table summarizes stock option activity for the three months ended March 29, 2015:
		Number		Weighted-			Weighted-Average	Total
		of		Average Exercise			Remaining	Intrinsic
		Shares		Price			Contractual Term	Value
		(In thousands)					(In years)	(In millions)
	Outstanding at December 28, 2014	2,828		$	26.11
	Granted	484		46.22
	Exercised	(573	)	15.43
	Canceled	(3	)	22
	Forfeited	(51	)	23.93
	Outstanding at March 29, 2015	2,685		$	32.06		4.3	$	37.7
	Exercisable at March 29, 2015	1,720		$	25.92		3.1	$	34.6
	Vested and expected to vest in the future	2,611		$	31.8		4.2	$	37.3
	The weighted-average per-share grant-date fair value of options granted during the three months ended March 29, 2015 and March 30, 2014 was $10.99 and $11.85, respectively. The total intrinsic value of options exercised during the three months ended March 29, 2015 and March 30, 2014 was $17.7 million and $6.5 million, respectively. Cash received from option exercises for the three months ended March 29, 2015 and March 30, 2014 was $8.8 million and $7.2 million, respectively.
	The total compensation expense recognized related to the Company’s outstanding options was $0.8 million and $1.5 million for the three months ended March 29, 2015 and March 30, 2014, respectively.
	There was $9.4 million of total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock options granted as of March 29, 2015. This cost is expected to be recognized over a weighted-average period of 2.3 years and will be adjusted for any future changes in estimated forfeitures.
	Restricted Stock Awards: The following table summarizes restricted stock award activity for the three months ended March 29, 2015:
		Number of		Weighted-
		Shares		Average
				Grant-
				Date Fair
				Value
		(In thousands)
	Nonvested at December 28, 2014	558		$	35.51
	Granted	208		46.32
	Vested	(221	)	29.99
	Forfeited	(7	)	37.05
	Nonvested at March 29, 2015	538		$	41.93
	The weighted-average per-share grant-date fair value of restricted stock awards granted during the three months ended March 29, 2015 and March 30, 2014 was $46.32 and $42.55, respectively. The fair value of restricted stock awards vested during the three months ended March 29, 2015 and March 30, 2014 was $6.6 million and $6.8 million, respectively. The total compensation expense recognized related to the Company’s outstanding restricted stock awards was $2.0 million for each of the three months ended March 29, 2015 and March 30, 2014.
	As of March 29, 2015, there was $17.2 million of total unrecognized compensation cost, net of forfeitures, related to nonvested restricted stock awards. That cost is expected to be recognized over a weighted-average period of 1.9 years.
	Performance Units: The Company granted 66,509 and 79,463 performance units during the three months ended March 29, 2015 and March 30, 2014, respectively, as part of the Company’s executive incentive program. The weighted-average per-share grant-date fair value of performance units granted during the three months ended March 29, 2015 and March 30, 2014 was $46.83 and $42.84, respectively. The total compensation expense recognized related to performance units was $1.1 million and $1.0 million for the three months ended March 29, 2015 and March 30, 2014, respectively. As of March 29, 2015, there were 210,275 performance units outstanding and subject to forfeiture, with a corresponding liability of $3.3 million recorded in accrued expenses and other current liabilities.
	Stock Awards: The Company generally grants stock awards only to non-employee members of the Board. The Company granted 544 shares to a new non-employee member of the Board during the three months ended March 29, 2015. The weighted-average per-share grant-date fair value of the stock award granted during the three months ended March 29, 2015 was $45.98. The total compensation expense recognized related to this stock award was $0.03 million during the three months ended March 29, 2015.
	Employee Stock Purchase Plan: During the three months ended March 29, 2015, the Company issued 29,565 shares of common stock under the Company's Employee Stock Purchase Plan at a weighted-average price of $41.54 per share. During the three months ended March 30, 2014, the Company issued 31,854 shares of common stock under the Company's Employee Stock Purchase Plan at a weighted-average price of $39.17 per share. At March 29, 2015, an aggregate of 1.0 million shares of the Company’s common stock remained available for sale to employees out of the 5.0 million shares authorized by shareholders for issuance under this plan.

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets, Net	3 Months Ended
	Mar. 29, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	Goodwill and Intangible Assets, Net
	The Company tests goodwill and non-amortizing intangible assets at least annually for possible impairment. Accordingly, the Company completes the annual testing of impairment for goodwill and non-amortizing intangible assets on the later of January 1 or the first day of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill or non-amortizing intangible assets.
	The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of a two-step process. The first step is the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. The second step measures the amount of an impairment loss, and is only performed if the carrying value exceeds the fair value of the reporting unit. The Company performed its annual impairment testing for its reporting units as of January 1, 2015, its annual impairment date for fiscal year 2015. The Company concluded based on the first step of the process that there was no goodwill impairment, and the fair value exceeded the carrying value by more than 20.0% for each reporting unit. The long-term terminal growth rates for the Company’s reporting units ranged from 4.0% to 6.5% for the fiscal year 2015 impairment analysis. The range for the discount rates for the reporting units was 9.5% to 12.5%. Keeping all other variables constant, a 10.0% change in any one of the input assumptions for the various reporting units would still allow the Company to conclude, based on the first step of the process, that there was no impairment of goodwill.
	Subsequent to the 2015 annual impairment test, the Company realigned its organization, as discussed in Note 10. While the realignment did not have a significant impact on the fair values of the reporting units as discussed above, the realignment did result in a change in the composition of the Company's reportable segments. OneSource, the multivendor service offering business that serves the life sciences end market, was moved from the Environmental Health segment into the Human Health segment. As a result of the new alignment, the Company will reallocate goodwill from the Environmental Health segment to the Human Health segment based on the relative fair value, determined using the income approach, of the business. The change resulted in a preliminary goodwill reallocation of $27.0 million from the Environmental Health segment into the Human Health segment as of March 29, 2015.
	The Company has consistently employed the income approach to estimate the current fair value when testing for impairment of goodwill. A number of significant assumptions and estimates are involved in the application of the income approach to forecast operating cash flows, including markets and market share, sales volumes and prices, costs to produce, tax rates, capital spending, discount rates and working capital changes. Cash flow forecasts are based on approved business unit operating plans for the early years’ cash flows and historical relationships in later years. The income approach is sensitive to changes in long-term terminal growth rates and the discount rates. The long-term terminal growth rates are consistent with the Company’s historical long-term terminal growth rates, as the current economic trends are not expected to affect the long-term terminal growth rates of the Company. The Company corroborates the income approach with a market approach.
	The Company has consistently employed the relief from royalty model to estimate the current fair value when testing for impairment of non-amortizing intangible assets. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized. In addition, the Company evaluates the remaining useful lives of its non-amortizing intangible assets at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful lives of non-amortizing intangible assets are no longer indefinite, the assets will be tested for impairment. These intangible assets will then be amortized prospectively over their estimated remaining useful lives and accounted for in the same manner as other intangible assets that are subject to amortization. The Company performed its annual impairment testing as of January 1, 2015, and concluded that there was no impairment of non-amortizing intangible assets. An assessment of the recoverability of amortizing intangible assets takes place when events have occurred that may give rise to an impairment. No such events occurred during the first three months of fiscal year 2015.
	The changes in the carrying amount of goodwill for the period ended March 29, 2015 from December 28, 2014 were as follows:
		Human			Environmental			Consolidated
		Health			Health
		(In thousands)
	Balance at December 28, 2014	$	1,648,590		$	635,487		$	2,284,077
	Foreign currency translation	(23,024		)	(9,407		)	(32,431		)
	Acquisitions and other	33			1,529			1,562
	Balance at March 29, 2015	$	1,625,599		$	627,609		$	2,253,208
	Identifiable intangible asset balances at March 29, 2015 and December 28, 2014 by category were as follows:
		March 29,			December 28,
		2015			2014
		(In thousands)
	Patents	$	39,913		$	39,953
	Less: Accumulated amortization	(27,816		)	(27,200		)
	Net patents	12,097			12,753
	Trade names and trademarks	39,957			40,069
	Less: Accumulated amortization	(17,793		)	(16,936		)
	Net trade names and trademarks	22,164			23,133
	Licenses	59,183			59,631
	Less: Accumulated amortization	(42,439		)	(41,792		)
	Net licenses	16,744			17,839
	Core technology	296,665			298,491
	Less: Accumulated amortization	(190,519		)	(184,697		)
	Net core technology	106,146			113,794
	Customer relationships	400,510			402,185
	Less: Accumulated amortization	(164,551		)	(156,994		)
	Net customer relationships	235,959			245,191
	IPR&D	9,583			10,103
	Less: Accumulated amortization	(3,265		)	(3,132		)
	Net IPR&D	6,318			6,971
	Net amortizable intangible assets	399,428			419,681
	Non-amortizing intangible assets:
	Trade names and trademarks	70,584			70,584
	Total	$	470,012		$	490,265
	Total amortization expense related to definite-lived intangible assets was $19.8 million and $20.7 million for the three months ended March 29, 2015 and March 30, 2014, respectively. Estimated amortization expense related to definite-lived intangible assets for each of the next five years is $60.9 million for the remainder of fiscal year 2015, $71.9 million for fiscal year 2016, $62.3 million for fiscal year 2017, $49.2 million for fiscal year 2018, and $37.7 million for fiscal year 2019.

Warranty_Reserves

Warranty Reserves	3 Months Ended
	Mar. 29, 2015
Product Warranties Disclosures [Abstract]
Warranty Reserves	Warranty Reserves
	The Company provides warranty protection for certain products usually for a period of one year beyond the date of sale. The majority of costs associated with warranty obligations include the replacement of parts and the time for service personnel to respond to repair and replacement requests. A warranty reserve is recorded based upon historical results, supplemented by management’s expectations of future costs. Warranty reserves are included in “Accrued expenses and other current liabilities” on the condensed consolidated balance sheets.
	A summary of warranty reserve activity for the three months ended March 29, 2015 and March 30, 2014 is as follows:
		Three Months Ended
		March 29,			March 30,
		2015			2014
		(In thousands)
	Balance beginning of period	$	10,783		$	10,534
	Provision charged to income	4,158			4,077
	Payments	(3,762		)	(3,967		)
	Adjustments to previously provided warranties, net	79			(297		)
	Foreign currency translation and acquisitions	(387		)	10
	Balance end of period	$	10,871		$	10,357

Employee_Benefit_Plans

Employee Benefit Plans	3 Months Ended
	Mar. 29, 2015
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plans	Employee Postretirement Benefit Plans
	The following table summarizes the components of net periodic (credit) benefit cost for the Company’s various defined benefit employee pension and postretirement plans for the three months ended March 29, 2015 and March 30, 2014:
		Defined Benefit						Postretirement
		Pension Benefits						Medical Benefits
		Three Months Ended
		March 29,			March 30,			March 29,			March 30,
		2015			2014			2015			2014
		(In thousands)
	Service cost	$	1,106		$	1,030		$	27		$	24
	Interest cost	5,250			5,916			36			39
	Expected return on plan assets	(6,512		)	(6,263		)	(266		)	(241		)
	Amortization of prior service costs	(64		)	(71		)	—			—
	Net periodic (credit) benefit cost	$	(220	)	$	612		$	(203	)	$	(178	)
	During the three months ended March 29, 2015 and March 30, 2014, the Company contributed $4.9 million and $0.9 million, respectively, in the aggregate, to pension plans outside of the United States. During the three months ended March 29, 2015, the Company contributed $20.0 million to its defined benefit pension plan in the United States.
	In the third quarter of fiscal year 2014, the Company notified employees of its intention to terminate their employment as part of the Q3 2014 restructuring plan. The removal of these participants will decrease the expected future service lives in excess of the curtailment limit for one of the Company's pension plans, which will result in a curtailment gain. When the curtailment occurs, the curtailment will be measured and recorded when the notified employees are separated from the Company. As part of a curtailment, the Company is required to remeasure the assets and liabilities of the plan that has the curtailment based upon current discount rates and the fair value of the pension plan's assets as of the curtailment date, which may result in an additional gain or loss in addition to the curtailment gain. Employee separation is expected to be completed during the first half of fiscal year 2015.
	The Company recognizes actuarial gains and losses, unless an interim remeasurement is required, in operating results in the fourth quarter of the year in which the gains and losses occur, in accordance with the Company's accounting method for defined benefit pension plans and other postretirement benefits as described in Note 1 of the Company's audited consolidated financial statements and notes included in its 2014 Form 10-K. Such adjustments for gains and losses are primarily driven by events and circumstances beyond the Company's control, including changes in interest rates, the performance of the financial markets and mortality assumptions.

Derivatives_And_Hedging_Activi

Derivatives And Hedging Activities	3 Months Ended
	Mar. 29, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Hedging Activities	Derivatives and Hedging Activities
	The Company uses derivative instruments as part of its risk management strategy only, and includes derivatives utilized as economic hedges that are not designated as hedging instruments. By nature, all financial instruments involve market and credit risks. The Company enters into derivative instruments with major investment grade financial institutions and has policies to monitor the credit risk of those counterparties. The Company does not enter into derivative contracts for trading or other speculative purposes, nor does the Company use leveraged financial instruments. Approximately 60% of the Company’s business is conducted outside of the United States, generally in foreign currencies. The fluctuations in foreign currency can increase the costs of financing, investing and operating the business. The intent of these economic hedges is to offset gains and losses that occur on the underlying exposures from these currencies, with gains and losses resulting from the forward currency contracts that hedge these exposures.
	In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months, have no cash requirements until maturity, and are recorded at fair value on the Company’s condensed consolidated balance sheets. The unrealized gains and losses on the Company’s foreign currency contracts are recognized immediately in earnings, included in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from operating activities within the Company’s condensed consolidated statement of cash flows.
	Principal hedged currencies include the British Pound, Euro, Japanese Yen and Singapore Dollar. The Company held forward foreign exchange contracts, designated as economic hedges, with U.S. dollar equivalent notional amounts totaling $108.2 million, $95.0 million and $95.0 million at March 29, 2015, December 28, 2014 and March 30, 2014, respectively, and the fair value of these foreign currency derivative contracts was insignificant. The gains and losses realized on these foreign currency derivative contracts are not material. The duration of these contracts was generally 30 days or less during each of the three months ended March 29, 2015 and March 30, 2014.
	In addition, in connection with certain intercompany loan agreements the Company enters into forward foreign exchange contracts intended to hedge movements in foreign exchange rates prior to settlement of such intercompany loans denominated in foreign currencies. The Company records these hedges at fair value on the Company’s condensed consolidated balance sheets. The unrealized gains and losses on these hedges, as well as the gains and losses associated with the remeasurement of the intercompany loans, are recognized immediately in earnings, included in interest and other expense, net. The cash flows related to the settlement of these hedges are included in cash flows from financing activities within the Company’s condensed consolidated statement of cash flows.
	The combined Euro denominated notional amounts of these hedges was €273.7 million and €238.2 million as of March 29, 2015 and December 28, 2014, respectively. During the three months ended March 29, 2015, the Company settled one of these forward exchange contracts and entered into two more contracts that will also settle in fiscal year 2015. The net gains and losses on these derivatives, combined with the gains and losses on the remeasurement of the hedged intercompany loans were not material for the three months ending March 29, 2015. The Company received $15.6 million as a result of the settlement of these hedges in the three months ended March 29, 2015.
	The Company does not expect any material net pre-tax gains or losses to be reclassified from accumulated other comprehensive income into interest and other expense, net within the next twelve months.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 29, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements
	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities and accounts receivable. The Company believes it had no significant concentrations of credit risk as of March 29, 2015.
	The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during the three months ended March 29, 2015. The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition-related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value.
	Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.
	The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of March 29, 2015 and December 28, 2014 classified in one of the three classifications described above:
					Fair Value Measurements at March 29, 2015 Using:
		Total Carrying Value at March 29, 2015			Quoted Prices in			Significant Other			Significant
					Active Markets			Observable Inputs			Unobservable
					(Level 1)			(Level 2)			Inputs
											(Level 3)
		(In thousands)
	Marketable securities	$	1,598		$	1,598		$	—		$	—
	Foreign exchange derivative assets	6,629			—			6,629			—
	Foreign exchange derivative liabilities	(575		)	—			(575		)	—
	Contingent consideration	(81		)	—			—			(81		)
					Fair Value Measurements at December 28, 2014 Using:
		Total Carrying Value at December 28, 2014			Quoted Prices in			Significant Other			Significant
					Active Markets			Observable Inputs			Unobservable
					(Level 1)			(Level 2)			Inputs
											(Level 3)
		(In thousands)
	Marketable securities	$	1,568		$	1,568		$	—		$	—
	Foreign exchange derivative assets	3,205			—			3,205			—
	Foreign exchange derivative liabilities	(302		)	—			(302		)	—
	Contingent consideration	(91		)	—			—			(91		)
	Level 1 and Level 2 Valuation Techniques:    The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity and fixed-income securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities.
	Marketable securities:    Include equity and fixed-income securities measured at fair value using the quoted market prices in active markets at the reporting date.
	Foreign exchange derivative assets and liabilities:    Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date. The Company’s foreign exchange derivative contracts are subject to master netting arrangements that allow the Company and its counterparties to net settle amounts owed to each other. Derivative assets and liabilities that can be net settled under these arrangements have been presented in the Company's consolidated balance sheet on a net basis and are recorded in other assets. As of both March 29, 2015 and December 28, 2014, none of the master netting arrangements involved collateral.
	Level 3 Valuation Techniques:    The Company’s Level 3 liabilities are comprised of contingent consideration related to acquisitions. For liabilities that utilize Level 3 inputs, the Company uses significant unobservable inputs. Below is a summary of valuation techniques for Level 3 liabilities.
	Contingent consideration:    The Company has classified its net liabilities for contingent consideration relating to its acquisitions within Level 3 of the fair value hierarchy because the fair value is determined using significant unobservable inputs, which included probability weighted cash flows. A description of the significant acquisitions is included within Note 2 to the Company's audited consolidated financial statements filed with the 2014 Form 10-K. Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period. Increases or decreases in the fair value of contingent consideration liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds or product development milestones during the earnout period. The Company may have to pay contingent consideration, related to acquisitions with open contingency periods, of up to $31.4 million as of March 29, 2015. As of March 29, 2015, the Company has recorded contingent consideration obligations relating to the acquisition of Tetra Teknolojik Sistemler Limited Sirketi with an estimated fair value of $0.1 million. The earnout period for acquisitions with open contingency periods does not exceed three years from the respective acquisition date, and the remaining weighted average earnout period at March 29, 2015 was six months.
	A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows:
		Three Months Ended
		March 29,			March 30,
		2015			2014
		(In thousands)
	Balance beginning of period	$	(91	)	$	(4,926	)
	Amounts paid and foreign currency translation	10			—
	Change in fair value (included within selling, general and administrative expenses)	—			(55		)
	Balance end of period	$	(81	)	$	(4,981	)
	The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1.
	The Company’s senior unsecured revolving credit facility, which provides for $700.0 million of revolving loans, had amounts outstanding, excluding letters of credit, of $479.0 million and $516.0 million as of March 29, 2015 and December 28, 2014, respectively. The interest rate on the Company’s senior unsecured revolving credit facility is reset at least monthly to correspond to variable rates that reflect currently available terms and conditions for similar debt. The Company had no change in credit standing during the first three months of fiscal year 2015. Consequently, the carrying value of the current year and prior year credit facilities approximate fair value and would be classified as Level 2.
	The Company's 2021 Notes, with a face value of $500.0 million, had an aggregate carrying value of $497.7 million, net of $2.3 million of unamortized original issue discount, and a fair value of $548.1 million as of March 29, 2015. The 2021 Notes had an aggregate carrying value of $497.7 million, net of $2.3 million of unamortized original issue discount, and a fair value of $542.7 million as of December 28, 2014. The fair value of the 2021 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. The Company's financing lease obligations had an aggregate carrying value of $39.0 million and $39.3 million as of March 29, 2015 and December 28, 2014, respectively. The carrying values of the Company's financing lease obligations approximated their fair value as there has been minimal change in the Company's incremental borrowing rate. As of March 29, 2015, the 2021 Notes and financing lease obligations were classified as Level 2.
	As of March 29, 2015, there has not been any significant impact to the fair value of the Company’s derivative liabilities due to credit risk. Similarly, there has not been any significant adverse impact to the Company’s derivative assets based on the evaluation of its counterparties’ credit risks.

Contingencies

Contingencies	3 Months Ended
	Mar. 29, 2015
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies
	The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (“PRP”) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company’s responsibility is established and when the cost can be reasonably estimated. The Company has accrued $12.0 million and $12.3 million as of March 29, 2015 and December 28, 2014, respectively, which represents its management’s estimate of the cost of the remediation of known environmental matters, and does not include any potential liability for related personal injury or property damage claims. The Company's environmental accrual is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. The cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that the majority of such accrued amounts could be paid out over a period of up to ten years. As assessment and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had, or are expected to have, a material adverse effect on the Company’s condensed consolidated financial statements. While it is possible that a loss exceeding the amounts recorded in the condensed consolidated financial statements may be incurred, the potential exposure is not expected to be materially different from those amounts recorded.
	The Company is subject to various claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of its business activities. Although the Company has established accruals for potential losses that it believes are probable and reasonably estimable, in the opinion of the Company’s management, based on its review of the information available at this time, the total cost of resolving these contingencies at March 29, 2015 should not have a material adverse effect on the Company’s condensed consolidated financial statements. However, each of these matters is subject to uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 29, 2015
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted and Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s condensed consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations.
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers. Under this new guidance, an entity should use a five-step process to recognize revenue, which depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires new disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The initial provisions of this guidance are effective for interim and annual periods beginning after December 15, 2016. In April 2015, the Financial Accounting Standards Board tentatively decided to defer the effective date of the standard for one year to annual periods beginning after December 15, 2017, with early adoption permitted for annual periods beginning after December 15, 2016. The Company is evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company’s consolidated financial position, results of operations and cash flows.
	In April 2015, the Financial Accounting Standards Board issued Accounting Standards Update No. 2015-04, Practical Expedient for the Measurement Date of an Employer’s Defined Benefit Obligation and Plan Assets. Under this new guidance, an entity with a fiscal year-end that does not coincide with a calendar month-end (for example an entity that has a 52/53 week fiscal year) has the ability, as a practical expedient, to measure its defined benefit retirement obligations and related plan assets as of the month-end that is closest to its fiscal year end. An entity that uses this election must disclose it and consistently apply the practical expedient from year to year and to all of its defined benefit plans. The provisions of this guidance are effective for interim and annual periods beginning after December 15, 2015. Prospective application is required, and early adoption is permitted. The Company is evaluating the requirements of this guidance and expects to early adopt this guidance for its current fiscal year ending January 3, 2016 and for any interim period during the current fiscal year. The adoption is not expected to have a material impact on the Company's consolidated financial position, results of operations and cash flows.

Business_Combinations_Tables

Business Combinations (Tables)	3 Months Ended
	Mar. 29, 2015
Business Acquisition [Line Items]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	The total purchase price for the acquisitions in fiscal year 2014 has been allocated to the estimated fair values of assets acquired and liabilities assumed as follows:
		Perten			2014 Other
		(Preliminary)
		(In thousands)
	Fair value of business combination:
	Cash payments	$	269,937		$	17,898
	Working capital and other adjustments	—			151
	Less: cash acquired	(16,732		)	(124		)
	Total	$	253,205		$	17,925
	Identifiable assets acquired and liabilities assumed:
	Current assets	$	32,805		$	1,965
	Property, plant and equipment	1,485			125
	Other assets	—			364
	Identifiable intangible assets:
	Core technology	16,000			1,705
	Trade names	7,000			—
	Customer relationships	87,000			6,800
	IPR&D	—			1,266
	Goodwill	164,164			15,981
	Deferred taxes	(31,454		)	(3,072		)
	Deferred revenue	—			(589		)
	Liabilities assumed	(16,195		)	(2,333		)
	Debt assumed	(7,600		)	(4,287		)
	Total	$	253,205		$	17,925

Discontinued_Operations_Tables

Discontinued Operations (Tables)	3 Months Ended
	Mar. 29, 2015
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	Summary pre-tax operating results of discontinued operations, which include the periods prior to disposition, were as follows:
		Three Months Ended
		March 29,			March 30,
		2015			2014
		(In thousands)
	Sales	$	20		$	1,294
	Costs and expenses	57			2,324
	Loss from discontinued operations before income taxes	$	(37	)	$	(1,030	)

Restructuring_and_Lease_Charge1

Restructuring and Lease Charges, Net (Tables)	3 Months Ended
	Mar. 29, 2015
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table summarizes the number of employees reduced, the initial restructuring or contract termination charges by operating segment, and the dates by which payments were substantially completed, or the expected dates by which payments will be substantially completed, for restructuring actions during fiscal year 2014:
				Initial Restructuring or Contract Termination Charges							Total		Date or Expected Date Payments Substantially Completed by
		Headcount Reduction		Human Health				Environmental Health
		(In thousands, except headcount data)
	Q3 2014 Plan	152		$	7,126			$	5,925		$	13,051	Q3 FY2015
	Q2 2014 Plan	22		545				190			735		Q2 FY2015
	Q1 2014 Plan	17		370				197			567		Q4 FY2014
	2014 Contract Termination Charges	—		—				1,545			1,545		Q4 FY2015
Schedule of Restructuring Plan Activity [Table Text Block]	The following table summarizes the Company's restructuring and contract termination accrual balances and related activity by restructuring plan, as well as contract termination, during the three months ended March 29, 2015:
		Balance at December 28, 2014			2015 Amounts Paid				Balance at March 29, 2015
		(In thousands)
	Q3 2014 Plan	$	10,059		$	(3,139	)		$	6,920
	Q2 2014 Plan	251			(8		)		243
	Q1 2014 Plan	92			—				92
	Previous Plans	13,124			(1,427		)		11,697
	Restructuring	23,526			(4,574		)		18,952
	Contract Termination	304			(89		)		215
	Total Restructuring and Contract Termination	$	23,830		$	(4,663	)		$	19,167

Interest_and_Other_Expense_Inc1

Interest and Other Expense (Income), Net (Tables)	3 Months Ended
	Mar. 29, 2015
Other Income and Expenses [Abstract]
Interest and Other Expense (Income), Net	Interest and other expense, net, consisted of the following:
		Three Months Ended
		March 29,			March 30,
		2015			2014
		(In thousands)
	Interest income	$	(209	)	$	(94	)
	Interest expense	9,388			9,219
	Other expense, net	242			2,164
	Total interest and other expense, net	$	9,421		$	11,289

Inventories_Net_Tables

Inventories, Net (Tables)	3 Months Ended
	Mar. 29, 2015
Inventory Disclosure [Abstract]
Schedule of Net Inventories	Inventories as of March 29, 2015 and December 28, 2014 consisted of the following:
		March 29,		December 28,
		2015		2014
		(In thousands)
	Raw materials	$	98,042	$	96,169
	Work in progress	20,106		18,783
	Finished goods	172,972		170,505
	Total inventories	$	291,120	$	285,457

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	3 Months Ended
	Mar. 29, 2015
Earnings Per Share [Abstract]
Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations	The following table reconciles the number of shares utilized in the earnings per share calculations:
		Three Months Ended
		March 29,	March 30,
		2015	2014
		(In thousands)
	Number of common shares—basic	112,641	112,553
	Effect of dilutive securities:
	Stock options	677	1,052
	Restricted stock awards	121	172
	Number of common shares—diluted	113,439	113,777
	Number of potentially dilutive securities excluded from calculation due to antidilutive impact	932	459

Industry_Segment_Information_T

Industry Segment Information (Tables)	3 Months Ended
	Mar. 29, 2015
Segment Reporting [Abstract]
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations	Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below:
		Three Months Ended
		March 29,			March 30,
		2015			2014
		(In thousands)
	Human Health
	Product revenue	$	231,147		$	239,030
	Service revenue	94,906			91,003
	Total revenue	326,053			330,033
	Operating income from continuing operations	55,882			43,982
	Environmental Health
	Product revenue	128,166			126,455
	Service revenue	72,682			74,122
	Total revenue	200,848			200,577
	Operating income from continuing operations	11,346			21,607
	Corporate
	Operating loss from continuing operations(1)	(9,847		)	(13,827		)
	Continuing Operations
	Product revenue	359,313			365,485
	Service revenue	167,588			165,125
	Total revenue	526,901			530,610
	Operating income from continuing operations	57,381			51,762
	Interest and other expense, net (see Note 5)	9,421			11,289
	Income from continuing operations before income taxes	$	47,960		$	40,473
	____________________________
	(1)	In 2002, Enzo Biochem, Inc. and Enzo Life Sciences, Inc. (collectively, “Enzo”) filed a complaint that alleged that the Company separately and together with other defendants breached distributorship and settlement agreements with Enzo, infringed Enzo's patents, engaged in unfair competition and fraud, and committed torts against Enzo by, among other things, engaging in commercial development and exploitation of Enzo's patented products and technology. The Company entered into a settlement agreement with Enzo dated June 20, 2014 and during fiscal year 2014 paid $7.0 million into a designated escrow account to resolve this matter, of which $3.7 million had been accrued in previous years and $3.3 million was recorded in the second quarter of fiscal year 2014. In addition, $3.2 million of expenses were incurred and recorded in preparation for the trial during the three months ended March 30, 2014

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 29, 2015
Stockholders' Equity Note [Abstract]
Components of Accumulated Other Comprehensive Loss	The components of accumulated other comprehensive income consisted of the following:
		March 29,			December 28,
		2015			2014
		(In thousands)
	Foreign currency translation adjustments	$	(365	)	$	23,332
	Unrecognized prior service costs, net of income taxes	1,575			1,575
	Unrealized net losses on securities, net of income taxes	(136		)	(107		)
	Accumulated other comprehensive income	$	1,074		$	24,800

Stock_Plans_Tables

Stock Plans (Tables)	3 Months Ended
	Mar. 29, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Total Compensation Recognized Related to Outstanding Equity Awards	The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance units and stock grants, net of estimated forfeitures, included in the Company’s condensed consolidated statements of operations for the three months ended March 29, 2015 and March 30, 2014:
		Three Months Ended
		March 29,			March 30,
		2015			2014
		(In thousands)
	Cost of product and service revenue	$	249		$	333
	Research and development expenses	159			141
	Selling, general and administrative expenses	3,579			4,042
	Total stock-based compensation expense	$	3,987		$	4,516
Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model	The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows:
		Three Months Ended
		March 29,		March 30,
		2015		2014
	Risk-free interest rate	1.3	%	1.5	%
	Expected dividend yield	0.6	%	0.7	%
	Expected lives	5 years		5 years
	Expected stock volatility	26.5	%	30.9	%
Summary of Stock Option Activity	The following table summarizes stock option activity for the three months ended March 29, 2015:
		Number		Weighted-			Weighted-Average	Total
		of		Average Exercise			Remaining	Intrinsic
		Shares		Price			Contractual Term	Value
		(In thousands)					(In years)	(In millions)
	Outstanding at December 28, 2014	2,828		$	26.11
	Granted	484		46.22
	Exercised	(573	)	15.43
	Canceled	(3	)	22
	Forfeited	(51	)	23.93
	Outstanding at March 29, 2015	2,685		$	32.06		4.3	$	37.7
	Exercisable at March 29, 2015	1,720		$	25.92		3.1	$	34.6
	Vested and expected to vest in the future	2,611		$	31.8		4.2	$	37.3
Summary of Restricted Stock Award Activity	The following table summarizes restricted stock award activity for the three months ended March 29, 2015:
		Number of		Weighted-
		Shares		Average
				Grant-
				Date Fair
				Value
		(In thousands)
	Nonvested at December 28, 2014	558		$	35.51
	Granted	208		46.32
	Vested	(221	)	29.99
	Forfeited	(7	)	37.05
	Nonvested at March 29, 2015	538		$	41.93

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 29, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the period ended March 29, 2015 from December 28, 2014 were as follows:
		Human			Environmental			Consolidated
		Health			Health
		(In thousands)
	Balance at December 28, 2014	$	1,648,590		$	635,487		$	2,284,077
	Foreign currency translation	(23,024		)	(9,407		)	(32,431		)
	Acquisitions and other	33			1,529			1,562
	Balance at March 29, 2015	$	1,625,599		$	627,609		$	2,253,208
Identifiable Intangible Asset Balances	Identifiable intangible asset balances at March 29, 2015 and December 28, 2014 by category were as follows:
		March 29,			December 28,
		2015			2014
		(In thousands)
	Patents	$	39,913		$	39,953
	Less: Accumulated amortization	(27,816		)	(27,200		)
	Net patents	12,097			12,753
	Trade names and trademarks	39,957			40,069
	Less: Accumulated amortization	(17,793		)	(16,936		)
	Net trade names and trademarks	22,164			23,133
	Licenses	59,183			59,631
	Less: Accumulated amortization	(42,439		)	(41,792		)
	Net licenses	16,744			17,839
	Core technology	296,665			298,491
	Less: Accumulated amortization	(190,519		)	(184,697		)
	Net core technology	106,146			113,794
	Customer relationships	400,510			402,185
	Less: Accumulated amortization	(164,551		)	(156,994		)
	Net customer relationships	235,959			245,191
	IPR&D	9,583			10,103
	Less: Accumulated amortization	(3,265		)	(3,132		)
	Net IPR&D	6,318			6,971
	Net amortizable intangible assets	399,428			419,681
	Non-amortizing intangible assets:
	Trade names and trademarks	70,584			70,584
	Total	$	470,012		$	490,265

Warranty_Reserves_Tables

Warranty Reserves (Tables)	3 Months Ended
	Mar. 29, 2015
Product Warranties Disclosures [Abstract]
Warranty Reserve Activity	A summary of warranty reserve activity for the three months ended March 29, 2015 and March 30, 2014 is as follows:
		Three Months Ended
		March 29,			March 30,
		2015			2014
		(In thousands)
	Balance beginning of period	$	10,783		$	10,534
	Provision charged to income	4,158			4,077
	Payments	(3,762		)	(3,967		)
	Adjustments to previously provided warranties, net	79			(297		)
	Foreign currency translation and acquisitions	(387		)	10
	Balance end of period	$	10,871		$	10,357

Employee_Benefit_Plans_Tables

Employee Benefit Plans (Tables)	3 Months Ended
	Mar. 29, 2015
Compensation and Retirement Disclosure [Abstract]
Components of Net Periodic Benefit Cost (Credit)	The following table summarizes the components of net periodic (credit) benefit cost for the Company’s various defined benefit employee pension and postretirement plans for the three months ended March 29, 2015 and March 30, 2014:
		Defined Benefit						Postretirement
		Pension Benefits						Medical Benefits
		Three Months Ended
		March 29,			March 30,			March 29,			March 30,
		2015			2014			2015			2014
		(In thousands)
	Service cost	$	1,106		$	1,030		$	27		$	24
	Interest cost	5,250			5,916			36			39
	Expected return on plan assets	(6,512		)	(6,263		)	(266		)	(241		)
	Amortization of prior service costs	(64		)	(71		)	—			—
	Net periodic (credit) benefit cost	$	(220	)	$	612		$	(203	)	$	(178	)

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 29, 2015
Fair Value Disclosures [Abstract]
Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis	The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of March 29, 2015 and December 28, 2014 classified in one of the three classifications described above:
					Fair Value Measurements at March 29, 2015 Using:
		Total Carrying Value at March 29, 2015			Quoted Prices in			Significant Other			Significant
					Active Markets			Observable Inputs			Unobservable
					(Level 1)			(Level 2)			Inputs
											(Level 3)
		(In thousands)
	Marketable securities	$	1,598		$	1,598		$	—		$	—
	Foreign exchange derivative assets	6,629			—			6,629			—
	Foreign exchange derivative liabilities	(575		)	—			(575		)	—
	Contingent consideration	(81		)	—			—			(81		)
					Fair Value Measurements at December 28, 2014 Using:
		Total Carrying Value at December 28, 2014			Quoted Prices in			Significant Other			Significant
					Active Markets			Observable Inputs			Unobservable
					(Level 1)			(Level 2)			Inputs
											(Level 3)
		(In thousands)
	Marketable securities	$	1,568		$	1,568		$	—		$	—
	Foreign exchange derivative assets	3,205			—			3,205			—
	Foreign exchange derivative liabilities	(302		)	—			(302		)	—
	Contingent consideration	(91		)	—			—			(91		)
Reconciliation of Beginning and Ending Level 3 Net Liabilities	A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows:
		Three Months Ended
		March 29,			March 30,
		2015			2014
		(In thousands)
	Balance beginning of period	$	(91	)	$	(4,926	)
	Amounts paid and foreign currency translation	10			—
	Change in fair value (included within selling, general and administrative expenses)	—			(55		)
	Balance end of period	$	(81	)	$	(4,981	)

Basis_of_Presentation_Basis_of

Basis of Presentation Basis of Presentation (Details)	12 Months Ended
	Dec. 28, 2014	Jan. 03, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating Cycle	52
Scenario, Forecast [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating Cycle		53

Business_Combinations_Narrativ

Business Combinations (Narrative) (Details) (USD $)	3 Months Ended		12 Months Ended	1 Months Ended	3 Months Ended
	Mar. 29, 2015	Mar. 30, 2014	Dec. 28, 2014	Dec. 28, 2014	Jun. 28, 2015	Dec. 29, 2013	Dec. 05, 2014	Oct. 21, 2014
Business Acquisition [Line Items]
Total transaction costs	$200,000	$100,000
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions	1 year
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	31,400,000
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	81,000	4,981,000	91,000	91,000		4,926,000
Business Combination, Contingent Consideration Arrangements, Maximum Period	3 years
Business Combination, Contingent Consideration Arrangements, Description	Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash.
Fiscal Year 2015 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Goodwill, Expected Tax Deductible Amount	30,000
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments	4,700,000
Perten Instruments Group AB [Member]
Business Acquisition [Line Items]
Business Acquisition, Goodwill, Expected Tax Deductible Amount							0
Fiscal Year 2014 Acquisitions (excluding Perten) [Member]
Business Acquisition [Line Items]
Cash paid to the shareholders			17,898,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt								-4,287,000
Business Acquisition, Goodwill, Expected Tax Deductible Amount								0
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			18,000,000
Environmental Health [Member] | Perten Instruments Group AB [Member]
Business Acquisition [Line Items]
Cash paid to the shareholders				269,937,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt							-7,600,000
Environmental Health [Member] | Minimum [Member] | Perten Instruments Group AB [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life				5 years
Environmental Health [Member] | Maximum [Member] | Perten Instruments Group AB [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life				10 years
Subsequent Event [Member]
Business Acquisition [Line Items]
Cash paid to the shareholders					$14,000,000

Business_Combinations_Fair_Val

Business Combinations (Fair Values of the Business Combinations and Allocations for the Acquisitions Completed) (Details) (USD $)	12 Months Ended	1 Months Ended
In Thousands, unless otherwise specified	Dec. 28, 2014	Dec. 28, 2014	Mar. 29, 2015	Oct. 21, 2014	Dec. 05, 2014
Business Acquisition [Line Items]
Goodwill	$2,284,077	$2,284,077	$2,253,208
Fiscal Year 2014 Acquisitions (excluding Perten) [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid	17,898
Goodwill				15,981
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments	-151
Cash Acquired	-124
Business Combination, Consideration Transferred	17,925
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets				1,965
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment				125
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets				364
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total				3,072
Business Acquisition, Purchase Price Allocation, Current and Non-current Liabilities, Deferred Revenue				-589
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities				2,333
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt				4,287
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net				17,925
Core Technology [Member] | Fiscal Year 2014 Acquisitions (excluding Perten) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles				1,705
Customer Relationships [Member] | Fiscal Year 2014 Acquisitions (excluding Perten) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles				6,800
In-process Research and Development [Member] | Fiscal Year 2014 Acquisitions (excluding Perten) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles				1,266
Trade Names [Member] | Fiscal Year 2014 Acquisitions (excluding Perten) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles				0
Human Health [Member]
Business Acquisition [Line Items]
Goodwill	1,648,590	1,648,590	1,625,599
Environmental Health [Member]
Business Acquisition [Line Items]
Goodwill	635,487	635,487	627,609
Environmental Health [Member] | Perten Instruments Group AB [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid		269,937
Goodwill					164,164
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments		0
Cash Acquired		-16,732
Business Combination, Consideration Transferred		253,205
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets					32,805
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment					1,485
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets					0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities, Total					31,454
Business Acquisition, Purchase Price Allocation, Current and Non-current Liabilities, Deferred Revenue					0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities					16,195
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt					7,600
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net					253,205
Environmental Health [Member] | Core Technology [Member] | Perten Instruments Group AB [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					16,000
Environmental Health [Member] | Customer Relationships [Member] | Perten Instruments Group AB [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					87,000
Environmental Health [Member] | In-process Research and Development [Member] | Perten Instruments Group AB [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					0
Environmental Health [Member] | Trade Names [Member] | Perten Instruments Group AB [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles					$7,000

Discontinued_Operations_Narrat

Discontinued Operations (Narrative) (Details) (USD $)	3 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014	Dec. 28, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Pre-tax gain (loss) on disposal of business unit	($13)	($72)
(Benefit from) provision for income taxes on discontinued operations and dispositions	-73	-375
Other Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Pre-tax gain (loss) on disposal of business unit	-10	-100
Microarray-based diagnostic testing laboratory in the United States [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Pre-tax gain (loss) on disposal of business unit			($100)

Discontinued_Operations_Operat

Discontinued Operations (Operating Results of Discontinued Operations Prior to Disposition) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Revenue	$20	$1,294
Disposal Group, Including Discontinued Operations, Costs and Expenses	57	2,324
Loss from discontinued operations before income taxes	($37)	($1,030)

Restructuring_and_Lease_Charge2

Restructuring and Lease Charges, Net (Narrative) (Details) (USD $)	Mar. 29, 2015	Dec. 28, 2014
Restructuring and Related Activities [Abstract]
Accrued restructuring and integration costs	$19,167,000	$23,830,000
Restructuring Reserve, Current	13,312,000	17,124,000
Restructuring Reserve, Noncurrent	$5,900,000	$6,700,000

Restructuring_and_Lease_Charge3

Restructuring and Lease Charges, Net (Schedule of Initial Charges) (Details) (USD $)	3 Months Ended				12 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014	Sep. 28, 2014	Jun. 29, 2014	Dec. 28, 2014
			employees	employees
Restructuring Cost and Reserve [Line Items]
Restructuring and lease charges, net	$0	$2,135
Q3 2014 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated			152
Restructuring and lease charges, net			13,051
Q2 2014 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated				22
Restructuring and lease charges, net				735
Q1 2014 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated		17
Restructuring and lease charges, net		567
2014 Contract Termination Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and lease charges, net					1,545
Human Health [Member] | Employee Severance [Member] | Q3 2014 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and lease charges, net			7,126
Human Health [Member] | Employee Severance [Member] | Q2 2014 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and lease charges, net				545
Human Health [Member] | Employee Severance [Member] | Q1 2014 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and lease charges, net		370
Environmental Health [Member] | Employee Severance [Member] | Q3 2014 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and lease charges, net			5,925
Environmental Health [Member] | Employee Severance [Member] | Q2 2014 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and lease charges, net				190
Environmental Health [Member] | Employee Severance [Member] | Q1 2014 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and lease charges, net		197
Environmental Health [Member] | Contract Termination [Member] | 2014 Contract Termination Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and lease charges, net					$1,545

Restructuring_and_Lease_Charge4

Restructuring and Lease Charges, Net (Schedule of Restructuring Plan Activity) (Details) (USD $)	3 Months Ended				12 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014	Sep. 28, 2014	Jun. 29, 2014	Dec. 28, 2014
Restructuring Reserve [Roll Forward]
Balance at beginning of period	$23,830
Restructuring and lease charges, net	0	2,135
Restructuring reserve Settled with Cash and Translation Adjustment	4,663
Balance at end of period	19,167
Employee Severance and Facility Closing [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period	23,526
Restructuring reserve Settled with Cash and Translation Adjustment	4,574
Balance at end of period	18,952
Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period	304
Restructuring reserve Settled with Cash and Translation Adjustment	89
Balance at end of period	215
Q3 2014 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and lease charges, net			13,051
Q3 2014 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period	10,059
Restructuring reserve Settled with Cash and Translation Adjustment	3,139
Balance at end of period	6,920
Q2 2014 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and lease charges, net				735
Q2 2014 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period	251
Restructuring reserve Settled with Cash and Translation Adjustment	8
Balance at end of period	243
Q1 2014 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Restructuring and lease charges, net		567
Q1 2014 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period	92
Restructuring reserve Settled with Cash and Translation Adjustment	0
Balance at end of period	92
2014 Contract Termination Charges [Member]
Restructuring Reserve [Roll Forward]
Restructuring and lease charges, net					1,545
Previous restructuring and integration plans [Member]
Restructuring Reserve [Roll Forward]
Balance at beginning of period	13,124
Restructuring reserve Settled with Cash and Translation Adjustment	1,427
Balance at end of period	11,697
Human Health [Member] | Q3 2014 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and lease charges, net			7,126
Human Health [Member] | Q2 2014 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and lease charges, net				545
Human Health [Member] | Q1 2014 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and lease charges, net		370
Environmental Health [Member] | Q3 2014 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and lease charges, net			5,925
Environmental Health [Member] | Q2 2014 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and lease charges, net				190
Environmental Health [Member] | Q1 2014 Restructuring Plan [Member] | Employee Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring and lease charges, net		197
Environmental Health [Member] | 2014 Contract Termination Charges [Member] | Contract Termination [Member]
Restructuring Reserve [Roll Forward]
Restructuring and lease charges, net					$1,545

Interest_and_Other_Expense_Inc2

Interest and Other Expense (Income), Net (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014
Other Income and Expenses [Abstract]
Interest income	($209)	($94)
Interest expense	9,388	9,219
Other expense, net	242	2,164
Total interest and other expense, net	$9,421	$11,289

Inventories_Net_Details

Inventories, Net (Details) (USD $)	Mar. 29, 2015	Dec. 28, 2014
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$98,042	$96,169
Work in progress	20,106	18,783
Finished goods	172,972	170,505
Total inventories, net	$291,120	$285,457

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014
Income Tax Contingency [Line Items]
Unrecognized tax benefits, gross	$30.70
Uncertain tax benefits if recognized that could affect the continuing operations effective tax rate	26.9
Uncertain tax positions including accrued interest, net of tax benefits and penalties, to be resolved within the next year	5.2
Open Tax Years by Major Tax Jurisdiction, Begin Date	2007
Tax Adjustments, Settlements, and Unusual Provisions	($1.80)	($2)

Debt_Details

Debt (Details) (USD $)	3 Months Ended	1 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Mar. 29, 2015	Oct. 25, 2011	Dec. 30, 2012	Dec. 28, 2014
Line of Credit, Maturing January 8, 2019 [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$700
Unsecured revolving credit facility, expiry date	8-Jan-19
Letters of credit issued and outstanding	12.2
Line of Credit Facility, Remaining Borrowing Capacity	208.8
Aggregate borrowings under the amended facility	479			516
2021 Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Unsecured senior notes, face value	500	500
Gross proceeds from the issuance of debt instrument		496.9
Senior unsecured notes issuance as percentage of principal amount		99.37%
Debt Instrument, Unamortized Discount	2.3	3.1		2.3
Long-term Debt, Gross	497.7			497.7
Debt instrument maturity date		25-Nov-21
Percentage of redemption of senior notes on or after August 15, 2021		100.00%
Percentage of redemption upon a change of control and a contemporaneous downgrade of the Notes		101.00%
2021 Notes [Member] | Treasury Rate [Member]
Basis spread on variable rate	0.45%
Financing Lease Obligations [Member]
Initial Fair Value of Other Long-term Debt Related to Financing Lease Obligations			29.3
Other Long-term Debt	39			39.3
Other Long-term Debt, Current	1.1			1.1
Other Long-term Debt, Noncurrent	37.9			38.2
Additional Financing Lease Obligations, funded by lessors			$11.50
Unsecured Revolving Credit Facility [Member] | Base Rate Option Two [Member]
Description of variable rate basis	Federal Funds
Unsecured Revolving Credit Facility [Member] | Eurocurrency Rate [Member]
Description of variable rate basis	Eurocurrency
Unsecured Revolving Credit Facility [Member] | Line of Credit, Maturing January 8, 2019 [Member]
Interest rate terms under amended senior unsecured revolving credit facility	The interest rates under the senior unsecured revolving credit facility are based on the Eurocurrency rate or the base rate at the time of borrowing, plus a margin. The base rate is the higher of (i)B the rate of interest in effect for such day as publicly announced from time to time by JP Morgan Chase Bank, N.A. as its "prime rate," (ii)B the Federal Funds rate plus 50 basis points or (iii) one-month Libor plus 1.00%.
Weighted average interest rates under amended senior unsecured revolving credit facility	The Eurocurrency margin as of March 29, 2015 was 108 basis points. The weighted average Eurocurrency interest rate as of March 29, 2015 was 0.18%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 1.26%.
Unsecured Revolving Credit Facility [Member] | Line of Credit, Maturing January 8, 2019 [Member] | Base Rate Option Three [Member]
Basis spread on variable rate	1.00%
Unsecured Revolving Credit Facility [Member] | Line of Credit, Maturing January 8, 2019 [Member] | Base Rate Option Two [Member]
Basis spread on variable rate	0.50%
Unsecured Revolving Credit Facility [Member] | Line of Credit, Maturing January 8, 2019 [Member] | Eurocurrency Rate [Member]
Basis spread on variable rate	1.08%
Weighted average Eurocurrency interest rate	0.18%
Weighted average effective Eurocurrency rate, including the margin	1.26%

Earnings_Per_Share_Schedule_of

Earnings Per Share (Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations) (Details)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014
Earnings Per Share [Abstract]
Number of common shares-basic	112,641	112,553
Effect of dilutive securities, Stock options	677	1,052
Effect of dilutive securities, Restricted stock	121	172
Number of common shares-diluted	113,439	113,777
Number of potentially dilutive securities excluded from calculation due to antidilutive impact	932	459

Industry_Segment_Information_I

Industry Segment Information Industry Segment Information Narrative (Details) (USD $)	3 Months Ended	12 Months Ended	3 Months Ended
In Millions, unless otherwise specified	Mar. 29, 2015	Dec. 28, 2014	Jun. 29, 2014	Dec. 29, 2013
	segments
Segment Reporting Information [Line Items]
Payments for Legal Settlements		$7
Loss Contingency Accrual				3.7
Number of Operating Segment	2
Enzo Biochem, Inc. Complaint [Member]
Segment Reporting Information [Line Items]
Loss Contingency Accrual, Period Increase (Decrease)			$3.30

Industry_Segment_Information_S

Industry Segment Information (Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations) (Details) (USD $)	3 Months Ended
	Mar. 29, 2015		Mar. 30, 2014
Segment Reporting Information [Line Items]
Revenue	$526,901,000		$530,610,000
Operating income (loss) from continuing operations	57,381,000		51,762,000
Interest and other expense, net	9,421,000		11,289,000
Income from continuing operations before income taxes	47,960,000		40,473,000
Sales Revenue, Goods, Net	359,313,000		365,485,000
Sales Revenue, Services, Net	167,588,000		165,125,000
Human Health [Member]
Segment Reporting Information [Line Items]
Revenue	326,053,000		330,033,000
Operating income (loss) from continuing operations	55,882,000		43,982,000
Sales Revenue, Goods, Net	231,147,000		239,030,000
Sales Revenue, Services, Net	94,906,000		91,003,000
Environmental Health [Member]
Segment Reporting Information [Line Items]
Revenue	200,848,000		200,577,000
Operating income (loss) from continuing operations	11,346,000		21,607,000
Sales Revenue, Goods, Net	128,166,000		126,455,000
Sales Revenue, Services, Net	72,682,000		74,122,000
Corporate [Member]
Segment Reporting Information [Line Items]
Operating income (loss) from continuing operations	-9,847,000	[1]	-13,827,000	[1]
Enzo Biochem, Inc. Complaint [Member]
Segment Reporting Information [Line Items]
Litigation Settlement, Expense			$3,200,000
[1]	In 2002, Enzo Biochem, Inc. and Enzo Life Sciences, Inc. (collectively, bEnzob) filed a complaint that alleged that the Company separately and together with other defendants breached distributorship and settlement agreements with Enzo, infringed Enzo's patents, engaged in unfair competition and fraud, and committed torts against Enzo by, among other things, engaging in commercial development and exploitation of Enzo's patented products and technology. The Company entered into a settlement agreement with Enzo dated June 20, 2014 and during fiscal year 2014 paid $7.0 million into a designated escrow account to resolve this matter, of which $3.7 million had been accrued in previous years and $3.3 million was recorded in the second quarter of fiscal year 2014. In addition, $3.2 million of expenses were incurred and recorded in preparation for the trial during the three months ended March 30, 2014.

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)	3 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 29, 2015	Dec. 28, 2014	Sep. 28, 2014	Jun. 29, 2014	Mar. 30, 2014	Jun. 28, 2015	Oct. 23, 2014
Schedule of Shareholders' Equity [Line Items]
Stock repurchase program, number of shares authorized to be repurchased							8,000,000
Number of common stock repurchased in open market	0
Stock repurchase program, number of shares remained available for repurchase	7,400,000
Repurchased Common Shares For Activity Pursuant to Equity Incentive Plans	85,739
Aggregate Cost of Repurchased Common Shares for Activity Pursuant to Equity Incentive Plans	$4
Cash dividends (per share)	$0.07	$0.07	$0.07	$0.07	$0.07
Dividends Payable, Amount	$7.90
Subsequent Event [Member]
Schedule of Shareholders' Equity [Line Items]
Cash dividends (per share)						$0.07

Stockholders_Equity_Components

Stockholders' Equity (Components Of Accumulated Other Comprehensive Loss) (Details) (USD $)	Mar. 29, 2015	Dec. 28, 2014
In Thousands, unless otherwise specified
Stockholders' Equity Note [Abstract]
Foreign currency translation adjustments, net of income taxes	($365)	$23,332
Unrecognized losses and prior service costs, net of income taxes	1,575	1,575
Unrealized net losses on securities, net of income taxes	-136	-107
Accumulated other comprehensive loss	$1,074	$24,800

Stock_Plans_Narrative_Details

Stock Plans (Narrative) (Details) (USD $)	3 Months Ended
	Mar. 29, 2015	Mar. 30, 2014	Dec. 28, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Former Stock-based Compensation Plans	1
Total income tax benefit recognized for stock-based compensation	$1,300,000	$1,600,000
Stock-based compensation costs capitalized as part of inventory	400,000	300,000
Total pre-tax stock-based compensation expense	3,987,000	4,516,000
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under plan	5,000,000
Number of Shares, Granted	29,565	31,854
Weighted-average grant-date fair value of stock granted (per share)	$41.54	$39.17
Shares available for grant under employee stock purchase plan	1,000,000
Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted	544
Weighted-average grant-date fair value of stock granted (per share)	$45.98
Total pre-tax stock-based compensation expense	30,000
Performance Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted	66,509	79,463
Weighted-average grant-date fair value of stock granted (per share)	$46.83	$42.84
Total pre-tax stock-based compensation expense	1,100,000	1,000,000
Awards/units outstanding	210,275
Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent	3,300,000
Restricted Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted	208,000
Weighted-average grant-date fair value of stock granted (per share)	$46.32	$42.55
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	7,000
Fair value of restricted stock awards vested	6,600,000	6,800,000
Total pre-tax stock-based compensation expense	2,000,000	2,000,000
Awards/units outstanding	538,000		558,000
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted	17,200,000
Weighted-average period for recognition of unrecognized compensation cost, years	1 year 11 months
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant-date fair value of options	$10.99	$11.85
Total intrinsic value of options exercised	17,700,000	6,500,000
Cash received from option exercises	8,800,000	7,200,000
Total pre-tax stock-based compensation expense	800,000	1,500,000
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted	$9,400,000
Weighted-average period for recognition of unrecognized compensation cost, years	2 years 3 months
2009 Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under plan	10,000,000

Stock_Plans_Summary_of_Total_C

Stock Plans (Summary of Total Compensation Recognized Related to Outstanding Stock Options) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense	$3,987	$4,516
Cost of sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense	249	333
Research and development expenses [Member ]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense	159	141
Selling, general and administrative and other expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total pre-tax stock-based compensation expense	$3,579	$4,042

Stock_Plans_WeightedAverage_As

Stock Plans (Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model) (Details)	3 Months Ended
	Mar. 29, 2015	Mar. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Risk-free interest rate	1.30%	1.50%
Expected dividend yield	0.60%	0.70%
Expected lives, years	5 years	5 years
Expected stock volatility	26.50%	30.90%

Stock_Plans_Summary_of_Stock_O

Stock Plans (Summary of Stock Option Activity) (Details) (USD $)	3 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Mar. 29, 2015
Stock option activity
Number of Shares, Outstanding at beginning of period	2,828
Number of Shares, Granted	484
Number of Shares, Exercised	-573
Number of Shares, Canceled	-3
Number of Shares, Forfeited	-51
Number of Shares, Outstanding at end of period	2,685
Number of Shares, Exercisable at end of period	1,720
Number of Shares, Vested and expected to vest in the future	2,611
Weighted-Average Price, Outstanding at beginning of period	$26.11
Weighted-Average Price, Granted	$46.22
Weighted-Average Price, Exercised	$15.43
Weighted-Average Price, Canceled	$22
Weighted-Average Price, Forfeited	$23.93
Weighted-Average Price, Outstanding at end of period	$32.06
Weighted-Average Price, Exercisable at end of period	$25.92
Weighted-Average Price, Vested and expected to vest in the future	$31.80
Weighted-Average Remaining Contractual Term in Years, Outstanding at end of period	4 years 3 months
Weighted-Average Remaining Contractual Term in Years, Exercisable at end of period	3 years 1 month
Weighted-Average Remaining Contractual Term in Years, Vested and expected to vest in the future	4 years 2 months
Total Intrinsic Value, Outstanding at end of period	$37.70
Total Intrinsic Value, Exercisable at end of period	34.6
Total Intrinsic Value, Vested and expected to vest in the future	$37.30

Stock_Plans_Summary_of_Restric

Stock Plans (Summary of Restricted Stock Award Activity) (Details) (Restricted Stock Awards [Member], USD $)	3 Months Ended
	Mar. 29, 2015	Mar. 30, 2014
Restricted Stock Awards [Member]
Restricted stock award activity
Number of Shares, Nonvested at beginning of period	558,000
Number of Shares, Granted	208,000
Number of Shares, Vested	-221,000
Number of Shares, Forfeited	-7,000
Number of Shares, Nonvested at end of period	538,000
Weighted-Average Grant-Date Fair Value, Nonvested at beginning of period	$35.51
Weighted-Average Grant-Date Fair Value, Granted	$46.32	$42.55
Weighted-Average Grant-Date Fair Value, Vested	$29.99
Weighted-Average Grant-Date Fair Value, Forfeited	$37.05
Weighted-Average Grant-Date Fair Value, Nonvested at end of period	$41.93

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets, Net (Narrative) (Details) (USD $)	3 Months Ended
	Mar. 29, 2015	Mar. 30, 2014	Jan. 01, 2015	Dec. 28, 2014
Goodwill and Intangible Assets Net [Line Items]
Reallocation of Goodwill Resulting from Realignment Within Operating Segments	$27,000,000
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount			20.00%
Goodwill	2,253,208,000			2,284,077,000
Change in any one of the input assumptions for the various reporting units	10.00%
Total amortization expense related to finite-lived intangible assets	19,800,000	20,700,000
Future Amortization Expense, Year One	60,900,000
Future Amortization Expense, Year Two	71,900,000
Future Amortization Expense, Year Three	62,300,000
Future Amortization Expense, Year Four	49,200,000
Future Amortization Expense, Year Five	37,700,000
Finite-Lived Intangible Assets, Net	$399,428,000			$419,681,000
Minimum [Member]
Goodwill and Intangible Assets Net [Line Items]
Long-term terminal growth rates for reporting units	4.00%
Discount rates for reporting units	9.50%
Maximum [Member]
Goodwill and Intangible Assets Net [Line Items]
Long-term terminal growth rates for reporting units	6.50%
Discount rates for reporting units	12.50%

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets, Net (Changes in the Carrying Amount of Goodwill) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015
Changes in the carrying amount of goodwill
Balance at beginning of period	$2,284,077
Foreign currency translation	-32,431
Goodwill, Acquisition, Earn Outs and Other Adjustments	1,562
Balance at end of period	2,253,208
Human Health [Member]
Changes in the carrying amount of goodwill
Balance at beginning of period	1,648,590
Foreign currency translation	-23,024
Goodwill, Acquisition, Earn Outs and Other Adjustments	33
Balance at end of period	1,625,599
Environmental Health [Member]
Changes in the carrying amount of goodwill
Balance at beginning of period	635,487
Foreign currency translation	-9,407
Goodwill, Acquisition, Earn Outs and Other Adjustments	1,529
Balance at end of period	$627,609

Goodwill_and_Intangible_Assets4

Goodwill and Intangible Assets, Net (Identifiable Intangible Asset Balances) (Details) (USD $)	Mar. 29, 2015	Dec. 28, 2014
In Thousands, unless otherwise specified
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Net amortizable intangible assets	$399,428	$419,681
Totals	470,012	490,265
Patents [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	39,913	39,953
Less: Accumulated amortization	-27,816	-27,200
Net amortizable intangible assets	12,097	12,753
Trade Names And Trademarks [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	39,957	40,069
Less: Accumulated amortization	-17,793	-16,936
Net amortizable intangible assets	22,164	23,133
Non-amortizing intangible assets	70,584	70,584
Licensing Agreements [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	59,183	59,631
Less: Accumulated amortization	-42,439	-41,792
Net amortizable intangible assets	16,744	17,839
Core Technology [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	296,665	298,491
Less: Accumulated amortization	-190,519	-184,697
Net amortizable intangible assets	106,146	113,794
Customer Relationships [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	400,510	402,185
Less: Accumulated amortization	-164,551	-156,994
Net amortizable intangible assets	235,959	245,191
In-process Research and Development [Member]
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]
Gross amortizable intangible assets	9,583	10,103
Less: Accumulated amortization	-3,265	-3,132
Net amortizable intangible assets	$6,318	$6,971

Warranty_Reserves_Details

Warranty Reserves (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014
Warranty reserve activity
Balance beginning of period	$10,783	$10,534
Provision charged to income	4,158	4,077
Payments	-3,762	-3,967
Adjustments to previously provided warranties, net	79	-297
Foreign currency translation and acquisitions	-387	10
Balance end of period	$10,871	$10,357

Employee_Benefit_Plans_Compone

Employee Benefit Plans (Components of Net Periodic Benefit Cost (Credit)) (Details) (USD $)	3 Months Ended
	Mar. 29, 2015	Mar. 30, 2014
Defined Benefit Pension Benefits [Member]
Components of net periodic benefit cost (credit)
Service cost	$1,106,000	$1,030,000
Interest cost	5,250,000	5,916,000
Expected return on plan assets	-6,512,000	-6,263,000
Amortization of prior service	-64,000	-71,000
Net periodic benefit cost (credit)	-220,000	612,000
Foreign Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Contributions by Employer	4,900,000	900,000
Postretirement Medical Benefits [Member]
Components of net periodic benefit cost (credit)
Service cost	27,000	24,000
Interest cost	36,000	39,000
Expected return on plan assets	-266,000	-241,000
Amortization of prior service	0	0
Net periodic benefit cost (credit)	-203,000	-178,000
United States Pension Plan of US Entity [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Contributions by Employer		$20,000,000

Derivatives_And_Hedging_Activi1

Derivatives And Hedging Activities (Details)	3 Months Ended
	Mar. 29, 2015	Mar. 30, 2014	Mar. 29, 2015	Mar. 30, 2014	Mar. 29, 2015	Dec. 28, 2014	Mar. 30, 2014	Mar. 29, 2015	Dec. 28, 2014
	USD ($)	USD ($)	European And Asian Currencies [Member]	European And Asian Currencies [Member]	Fair Value Hedging [Member]	Fair Value Hedging [Member]	Fair Value Hedging [Member]	Cash Flow Hedging [Member]	Cash Flow Hedging [Member]
					USD ($)	USD ($)	USD ($)	EUR (€)	EUR (€)
Derivative [Line Items]
Maximum maturity period for foreign exchange contracts, in months			12 months
Notional Amount of Cash Flow Hedge Instruments					$108,200,000	$95,000,000	$95,000,000	€ 273,700,000	€ 238,200,000
Payments for (Proceeds from) Hedge, Financing Activities	-15,563,000	0
Duration of foreign currency derivative contract, days			30 days	30 days
Company's business conducted outside United States	60.00%
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net	$0

Fair_Value_Measurements_Narrat

Fair Value Measurements (Narrative) (Details) (USD $)	3 Months Ended
	Mar. 29, 2015	Dec. 28, 2014	Mar. 30, 2014	Dec. 29, 2013	Oct. 25, 2011
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$31,400,000
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	81,000	91,000	4,981,000	4,926,000
Business Combination, Contingent Consideration Arrangements, Description	Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash.
Business Combination, Contingent Consideration Arrangements, Maximum Period	3 years
Business Combination, Contingent Consideration Arrangements, Weighted Average Period	0 years 6 months
Line of Credit, Maturing January 8, 2019 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	700,000,000
Revolving credit facility outstanding balance	479,000,000	516,000,000
2021 Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unsecured senior notes, face value	500,000,000				500,000,000
Long-term Debt, Gross	497,700,000	497,700,000
Debt Instrument, Unamortized Discount	2,300,000	2,300,000			3,100,000
Unsecured senior notes, fair value	548,100,000	542,700,000
Financing Lease Obligations [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Unsecured senior notes, fair value	$39,000,000	$39,300,000

Fair_Value_Measurements_Assets

Fair Value Measurements (Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis) (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Mar. 29, 2015	Dec. 28, 2014
In Thousands, unless otherwise specified
Carrying (Reported) Amount, Fair Value Disclosure [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Of Contingent Consideration Measured On Recurring Basis	($81)	($91)
Foreign exchange derivative liabilities, net	-575	-302
Marketable securities	1,598	1,568
Foreign exchange derivative assets, net	-6,629	-3,205
Quoted Prices In Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Of Contingent Consideration Measured On Recurring Basis	0	0
Foreign exchange derivative liabilities, net	0	0
Marketable securities	1,598	1,568
Foreign exchange derivative assets, net	0	0
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Of Contingent Consideration Measured On Recurring Basis	0	0
Foreign exchange derivative liabilities, net	-575	-302
Marketable securities	0	0
Foreign exchange derivative assets, net	-6,629	-3,205
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Of Contingent Consideration Measured On Recurring Basis	-81	-91
Foreign exchange derivative liabilities, net	0	0
Marketable securities	0	0
Foreign exchange derivative assets, net	$0	$0

Fair_Value_Measurements_Reconc

Fair Value Measurements (Reconciliation of Beginning and Ending Level 3 Net Liabilities) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 29, 2015	Mar. 30, 2014
Fair Value Disclosures [Abstract]
Balance beginning of period	($91)	($4,926)
Payments	10	0
Change in fair value (included within selling, general and administrative expenses)	0	-55
Balance end of period	($81)	($4,981)

Contingencies_Details

Contingencies (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 29, 2015	Dec. 28, 2014
	years
Commitments and Contingencies Disclosure [Abstract]
Management's estimate of total cost of ultimate disposition	$12	$12.30
Number of years over which estimated environmental cost will be paid	10